Overview

An Open-Label, Single- and Multi-Dose Pharmacokinetic (PK) Study of Oral Diltiazem and Topical Diltiazem Hydrochloride

Status:
Unknown status

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

The study is a single-center, open-label, safety and pharmacokinetic study in12 adult subjects with Anal Fissures. Subjects will be screened to determine eligibility within 7 days of treatment. There will be three parts to the study and all subjects will participate in each part.

Phase:

Phase 1

Details

Lead Sponsor:

Ventrus Biosciences, Inc

Treatments:

Diltiazem